CAS 1019640-33-5

N1,N1-Diethyl-N6-(6-methoxy-4-methyl-8-quinolinyl)-1,6-hexanediamine 4-methylbenzenesulfonate

Description:

N1,N1-Diethyl-N6-(6-methoxy-4-methyl-8-quinolinyl)-1,6-hexanediamine 4-methylbenzenesulfonate is a complex organic compound characterized by its unique structural features, which include a quinoline moiety and a sulfonate group. This compound typically exhibits properties such as solubility in polar solvents due to the presence of the sulfonate group, which enhances its ionic character. The quinoline structure contributes to its potential biological activity, often associated with various pharmacological effects. The presence of diethyl and hexanediamine groups suggests that it may have a moderate to high molecular weight and could exhibit basic properties due to the amine functionalities. Additionally, the methoxy and methyl substituents on the quinoline ring may influence its electronic properties and reactivity. Overall, this compound may be of interest in medicinal chemistry and drug development, particularly in the context of targeting specific biological pathways or receptors. However, detailed studies would be necessary to fully elucidate its properties and potential applications.

Formula: C₂₈H₄₁N₃O₄S

Synonyms:

• Sitamaquine - WR 6026 tosylate
• N1,N1-Diethyl-N6-(6-methoxy-4-methyl-8-quinolinyl)-1,6-hexanediamine 4-methylbenzenesulfonate
• Sitamaquine tosylate
• N,N-diethyl-N'-[4-methyl-6-(methyloxy)-8-quinolinyl]-1,6-hexanediamine tosylate
• Sitamaquine tosylate >=98% (HPLC)

Sitamaquine Tosylate

Controlled Product

CAS: 1019640-33-5

Formula: C₂₁H₃₃N₃O•C₇H₈O₃S

Color and Shape: Neat

Molecular weight: 515.71

Ref: TR-S493503

Sitamaquine Tosylate

CAS: 1019640-33-5

Sitamaquine Tosylate is an inhibitor of the protein kinase that is involved in the transforming growth factor beta (TGF-β) signaling pathway. It has been shown to inhibit TGF-β-mediated tumor cell proliferation and induce apoptosis in vitro and in vivo. Selumetinib, a drug that inhibits the same protein kinase, has been shown to have synergistic effects when combined with Sitamaquine Tosylate. This combination therapy may be used to treat cancer by inhibiting tumor growth.

Formula: C₂₁H₃₃N₃O·C₇H₈O₃S

Purity: Min. 95%

Molecular weight: 343.51 g/mol

Ref: 3D-UQB64033

Sitamaquine tosylate

CAS: 1019640-33-5

Sitamaquine: antileishmanial, targets L. donovani species, EC50 = 9.5-19.8 μM, inhibits mitochondrial complex II, induces apoptosis in promastigotes.

Formula: C₂₈H₄₁N₃O₄S

Color and Shape: Solid

Molecular weight: 515.71

Ref: TM-T37469